With no proprietary “strong buy” signals and a bearish MACD expansion, the near-term setup favors waiting/holding rather than chasing an entry.
Short-term pattern stats are not compelling (only ~0.3% expected move next week; ~3.22% next month), which doesn’t suit an impatient “buy now” approach.
Technical Analysis
Price context: Post-market 4.52 (-1.09%); pre-market was -4.91% and regular session +1.12% → mixed tape but currently leaning soft.
Trend (moving averages): Bullish structure (SMA_5 > SMA_20 > SMA_200) suggests the broader trend had turned up.
Momentum (MACD): Histogram -0.0467 and negatively expanding → bearish momentum is strengthening short-term, often preceding further weakness or failed bounces.
RSI (6): 44.36 (neutral-to-weak) → not oversold enough to signal a high-conviction dip-buy.
Implication: At ~4.52 the stock is below pivot and close to S1, which can bounce, but MACD suggests the higher-probability move is continued chop/down unless it reclaims and holds above ~5.81.
Positive Catalysts
and reverses, a technical bounce setup could develop quickly due to proximity of support.
Neutral/Negative Catalysts
Bearish MACD expanding below zero signals deteriorating momentum and raises risk of breaking nearby support.
Price is well below pivot (5.809), indicating the market is not currently valuing it in an “uptrend continuation” zone.
News item about Teradyne is not directly additive to FiEE and may be irrelevant/sector noise rather than a true catalyst for FIEE.
Trading trends: Hedge funds neutral and insiders neutral → no strong accumulation signal from sophisticated/insider flows.
Financial Performance
Latest quarter provided: 2025/Q3
Revenue: 1,939,542 (0.00% YoY) → no YoY growth in the quarter.
Net Income: -252,985 (-59.53% YoY) → losses widened materially.
EPS: -0.04 (-81.82% YoY) → profitability per share deteriorated.
Gross Margin: 84.96% (+162.30% YoY) → margin improved sharply, but it hasn’t translated into bottom-line profitability in this quarter.
Overall: quarter-level profitability trend is negative, despite strong margin and a separate FY2025 sales-growth headline.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price target change data was provided, so there is no visible Wall Street upgrade/downgrade trend to validate a buy.
Pros view (what would support a bullish thesis): strong FY sales growth headline, very high gross margin, ongoing R&D investment.
Cons view (what would keep pros cautious): latest quarter shows widening losses and weak revenue growth, plus current chart momentum has turned bearish.
Politicians / influential figures: No recent congress trading data available (no evidence of notable political buying/selling).
Wall Street analysts forecast FIEE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FIEE is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast FIEE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FIEE is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
